Veracyte, Inc.

May is #BladderCancerAwarenessMonth, a moment to recognize the people behind every diagnosis: patients navigating difficult decisions, the friends and family offering support along the way, and the healthcare professionals dedicated to delivering the best possible care. 🔹 #BladderCancer is one of the most common cancers worldwide 🔹 It does not behave the same way in every person, and differences in tumor biology can influence how the disease progresses and how it is treated 🔹 Ongoing advances from the research community continue to deepen our understanding and help guide more personalized treatment decisions At Veracyte, our commitment to advancing bladder cancer science is rooted in evidence, innovation, and collaboration. The #DecipherBladder test is a molecular subtyping tool that reveals underlying biological insights to help bring clarity to bladder cancer treatment decisions. Read our latest blog to learn how molecular insights are helping guide more personalized bladder cancer care -https://lnkd.in/ggRmrx_7    #BladderCancer #BladderCancerAwarenessMonth #DecipherBladder #MolecularSubtyping #PrecisionMedicine #Oncology #Urology #DecipherUrologicCancers Note: this information contains forward-looking statements - https://lnkd.in/gkcXNFPc  

Data from two significant phase III clinical trials using our Prosigna Breast and Decipher Prostate tests will be presented at the 2026 American Society of Clinical Oncology Annual Meeting (#ASCO26), taking place from May 29 through June 2 in Chicago. | Key Highlights | The OPTIMA and ENZAMET trial presentations are expected to provide practice-changing evidence demonstrating how Veracyte’s genomic tests can guide treatment decisions in both early-stage breast cancer and metastatic prostate cancer. 🔹 #ProsignaBreast: The results from the #OPTIMA study will address a key clinical question: which breast cancer patients would benefit from chemotherapy, and which may be able to safely avoid it – and its lasting side effects.  🔹 #DecipherProstate: The independent analysis of results from the #ENZAMET trial will assess the ability of the Decipher Prostate test to identify which patients with metastatic prostate cancer are most likely to benefit from adding chemotherapy to their treatment plan. | Resources | 🔗 Read the full press release: https://lnkd.in/gCrcRqSk  🔗 Event information: https://lnkd.in/gMfpXK_a  📄 Prosigna Breast Risk of Recurrence test: https://lnkd.in/ggEPQM2M 📄 Decipher Prostate test: https://lnkd.in/ggnNwfad #ASCO2026 #ClinicalTrials #ClinicalResearch #PrecisionMedicine #CancerPrognosis #CancerDiagnostics #MolecularSubtyping #OncologyResearch #CancerResearch #BreastCancer #ProstateCancer #DecipherUrologicCancers #RealWorldData Note: this information contains forward-looking statements - https://lnkd.in/gkcXNFPc  

#TeamVeracyte is in Washington, DC this weekend for the American Urological Association’s (#AUA2026) Annual Meeting, May 15–18. Stop by Booth 3405 to learn how our Decipher tests bring insight to prostate and bladder cancer care. 🔹 #DecipherProstate: Delivering genomic information to support clinical decision-making across the prostate cancer continuum 🔹 #DecipherBladder: Molecular subtyping that provides deep biological insight to support more individualized bladder cancer care 🔹 #DecipherGRID: Proprietary research-use-only database designed to help advance the understanding of urologic cancers at the molecular level | Resources | 🔗 Event details and full presentation schedule - https://lnkd.in/gkAQVtRM #AUA26 #DecipherUrologicCancers #UrologicCancer #ProstateCancer #BladderCancer #PrecisionMedicine #CancerDiagnostics

We are pleased to announce that we received Medicare coverage for our #TrueMRD Monitoring Test for patients with muscle-invasive bladder cancer (MIBC). The TrueMRD Test will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte's first minimal residual disease (#MRD) offering and the only commercially available truly whole-genome MRD test to come to market. | Key Highlights | This milestone supports clinicians in monitoring patients with MIBC for recurrence following definitive treatment with curative intent: 🔹 #ClinicalEvidence: PAGER, a pivotal prospective study published in European Urology, evaluated more than 900 blood and tissue samples from 112 patients with MIBC. In this study, the TrueMRD MIBC test detected disease recurrence a median of 131 days earlier than imaging. 🔹 #WholeGenomeMRD: Unlike approaches that track a limited set of genetic targets, TrueMRD analyzes patient-specific tumor variants across the entire genome in every sample tested. 🔹 #TrueMRDplatform: Supports significant ongoing research in MIBC, including the #TOMBOLA trial evaluating ctDNA-guided adjuvant immunotherapy and the NEO-BLAST trial assessing bladder-sparing approaches | Resources | 🔗 Read the full press release - https://lnkd.in/gr-9rEED  🔗 Learn about the TrueMRD Monitoring Test for MIBC -  https://lnkd.in/gwb-y6qg #MuscleInvasiveBladderCancer #BladderCancer #MRD #WholeGenomeSequencing #CancerDiagnostics #PrecisionMedicine #VeracyteDiagnosticsPlatform Note: this information contains forward-looking statements - https://lnkd.in/gkcXNFPc   

An insightful discussion from BackTable Urology on the role of biomarkers, including the #DecipherProstate test, to inform prostate cancer management across the disease continuum. #DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #Biomarkers #ClinicalResearch #Urology #CancerDiagnostics #MolecularDiagnostics

More than 15 studies focused on our Decipher portfolio will be presented at the American Urological Association's (#AUA2026) Annual Meeting, taking place May 15–18 in Washington, DC. | Key Highlights | The data showcases the growing impact of Decipher Bladder and Decipher Prostate tests in supporting personalized patient care: 🔹 #DecipherBladder: Insights into the role of molecular subtyping in informing bladder cancer management 🔹 #DecipherProstate: National-scale real-world data analyses demonstrating how Decipher Prostate informs treatment decisions 🔹 #DecipherGRID: Additional real-world data from the Decipher GRID (Genomic Resource for Intelligent Discovery) proprietary research-use-only database continues to fuel the flywheel of evidence in urologic cancers through ongoing research studies | Resources | 🔗 Read the full press release - https://lnkd.in/grWNMkXA    🔗 Event information: https://lnkd.in/gkAQVtRM    📄 Decipher Prostate: https://lnkd.in/g-739FJD    📄 Decipher Bladder: https://lnkd.in/gABg8Xmb 📄 Decipher GRID: https://lnkd.in/gBBiQVKB    #DecipherUrologicCancers #UrologicCancer #ProstateCancer #BladderCancer #PrecisionMedicine #RealWorldData #ClinicalResearch #MolecularSubtyping #CancerDiagnostics #AUA26 Note: this information contains forward-looking statements - https://lnkd.in/gkcXNFPc   

We will report financial results for the first quarter of 2026 on May 5, 2026 at 4:30 PM ET. Join our conference call and webcast to learn more about the financial results and receive a general business update. Access the live audio webcast here: https://lnkd.in/gTMvRAap #Q1Earnings #FinancialResults #InvestorRelations #Biotech #Diagnostics #VCYT #CancerDiagnostics #PrecisionMedicine Note: this information contains forward-looking statements - https://lnkd.in/gpHMFcjH

We're excited to announce that the Afirma GRID (Genomic Resource for Intelligent Discovery) data resource is expanding from 36 to 50 data points to further accelerate scientific discoveries in thyroid nodules and thyroid cancer. | About #AfirmaGRID | The Afirma GRID proprietary research-use-only database is designed to help clinicians advance the understanding of thyroid nodules and thyroid cancer at the molecular level. Afirma GRID data has contributed to a growing number of abstracts presented in collaboration with notable institutions from around the world, with a significant increase in research outputs throughout 2025. GRID data is for research use only and is not intended to guide patient management. 🔬 Afirma GRID data is available through three access pathways: 🔹 For ordering clinicians: An optional research-use-only report that provides a subset of the signatures is available when ordering Afirma GSC. 🔹 For ordering institutions: A research data set of the signatures database for patients tested at your practice/institution. 🔹 For select research projects: A custom collaboration across our data set around mutually defined research goals designed to advance the science. | Resources | Interested in conducting research or learning more about the Afirma GRID data resource? 🔗 Learn more about the Afirma GRID data resource -  https://lnkd.in/g-fDfVPM   📧 Contact us to get started - https://lnkd.in/gY_rjiAy  #ThyroidResearch #ThyroidCancer #ThyroidNodules #Endocrinology #ResearchCollaboration #GenomicResearch #MolecularDiagnostics #ClinicalResearch #ThyroidScience #DataScience #Pathology #ENT #MedicalResearch

We're looking forward to attending the American Society of Clinical Oncology (#ASCO) Annual Meeting in Chicago. The first results from the Phase III OPTIMA trial evaluating test-directed chemotherapy in breast cancer patients have been selected for oral presentation at #ASCO2026. | About OPTIMA | #OPTIMA is a randomized non-inferiority trial assessing Prosigna test-directed chemotherapy in patients with high clinical risk, ER-positive early breast cancer. The results will be presented by OPTIMA Chief Investigator Prof. Rob Stein of University College London (UCL) during the Breast Cancer Oral Abstract Session on Saturday, May 30. If you're attending ASCO, stop by our booth #13069. We look forward to connecting with you! | Resources | 🔗 Event information: https://lnkd.in/gs8iz4vB   📄 Learn more about OPTIMA: https://lnkd.in/epvmw8zK  #Prosigna #PrecisionMedicine #CancerCare #Oncology #ClinicalResearch #BreastCancer #IntrinsicMolecularSubtypes #BreastOncology #ClinicalTrials

We're excited to join the #AACE Annual Meeting this week in Las Vegas! Visit Booth #106 to meet our team and learn how Veracyte is using whole-transcriptome-derived analysis on every sample to provide an actionable #AfirmaGSC report and create the potential for novel research. Explore poster presentations highlighting how #Afirma can help guide confident treatment decisions for #thyroidnodules.    | Poster Presentation Details |    1. Molecular Characterization of Upper Pole Thyroid Nodules   Presenter: Dipika Mohan, M.D., Ph.D., Washington University in St Louis   📅 Date / Time: Wednesday, April 22 at 1:50 PM PDT   📍 Location: Poster Station 7    2. Preoperative mRNA Expression Signatures Associated with 2025 American Thyroid Association (ATA) Risk of Recurrence Categories   Presenter: Kara Kono, M.D., Scripps Clinic Medical Group   📅 Date / Time: Thursday, April 23 at 12:30 PM PDT   📍 Location: Poster Station 6    3. Risk of Structural Disease Recurrence Reclassification of Differentiated Thyroid Cancer from 2015 to 2025 American Thyroid Association Guidelines   Presenter: Kara Kono, M.D., Scripps Clinic Medical Group   📅 Date / Time: Thursday, April 23 at 12:30 PM PDT   📍 Location: Poster Station 5    We look forward to seeing you there!    | Resources | 🔗 Event information: https://lnkd.in/gpmC9nuu 📄 Download the Afirma 2025 Research Collection: https://lnkd.in/grE8-k4c #AACE2026 #AfirmaGSC #AfirmaThyroid #Endocrinology #ThyroidNodules #ThyroidHealth #ClinicalEndocrinology #ThyroidCare #TeamVeracyte